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Purpose. The purpose of this study was to explore anecdotal evidence for an increase in the prevalence of autoimmune diseases in
family members of patients with Aicardi-Goutières syndrome (AGS). Methods. Pedigrees of patients and controls were analyzed
using chi-square and logistic regression to assess diﬀerences in reports of autoimmune disease among family members of cases
and controls. Data was collected at Children’s National Medical Center in Washington, DC, USA and at the International AicardiGoutières Syndrome Association Scientific Headquarters, C. Mondino National Institute of Neurology in Pavia, Italy. Results. The
number of individuals with reported autoimmune disease is significantly related to having a family member with AGS (χ 2 = 6.25,
P = 0.01); 10% (35/320) of relatives of patients with AGS had a reported autoimmune disease diagnosis compared to 5% (18/344)
of relatives of controls. There was a greater percent of maternal relatives of patients with AGS reporting autoimmune disease
(14.6%), compared to controls (6.8%), with the association being statistically significant. The association was not significant for
paternal relatives. Conclusion. The prevalence of autoimmune disease in relatives of children with AGS is significantly increased
compared to controls. More research is needed to better understand this association.

1. Introduction
Aicardi-Goutières syndrome (AGS) is a heritable neurologic
disorder with an immune basis. Patients most typically
present early in life with increased cerebrospinal fluid (CSF)
interferon alpha and markers of inflammation, elevated liver
enzymes, thrombocytopenia, intracranial calcifications and
leukoencephalopathy. Patients with AGS usually demonstrate severe neurologic dysfunction and life-long disability.
The immune basis of AGS was originally suspected by
Aicardi and Goutières, as a persistent CSF pleocytosis was
seen in aﬀected infants. Infants presented with what
appeared to be a congenital infection [1], and reports of
elevations of CSF IFNα [2] and neopterin [3, 4] further suggested that an immune process was at play. However, it was
not until the identification of AGS related mutations in

nucleases, including TREX1 and the three constituent subunits of RNase H2, as well as a nonnuclease, SAMHD1, that
the relationship between innate cellular immunity and AGS
began to be more fully understood.
Discovery of the genes associated with AGS allowed for
further definition of the phenotype. Most patients with AGS
were found to have homozygous or compound heterozygous
changes in these genes. AGS was also found to be allelic
with Cree encephalitis and an inherited infantile systemic
lupus erythematosus [5–8]. Heterozygous mutations in AGS
related genes have also been found in rare patients with
systemic lupus erythematosus (SLE) [9, 10] and familial
chilblain lupus (FCL) [11–13], which are both autoimmune
disorders. Studies in large populations of SLE patients
suggest that TREX1 single nucleotide polymorphisms may
also be related to neurologic manifestations and the presence
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of autoantibodies [10]. Additionally, mutations in TREX1
have been reported in patients with retinal vasculopathy with
cerebral leukodystrophy (RVCL) [14].
Of the five genes currently known to be associated with
AGS, four, TREX1 and RNASEH2A-C, encode proteins
that have nucleic acid metabolizing functions, or nucleases.
The fifth gene SAMHD1, encodes a protein that while
not specifically a nuclease is thought to degrade nucleic acid
precursors [15] and is upregulated by immune-stimulatory
DNA [16]. Mutations in these genes are thought to result
in the accumulation of endogenous nucleic acids. Growing
evidence suggests that this accumulation provokes a type 1
interferon response that results in the development of
pathogenic cytokines and autoantibodies that target the
brain and other organs [17].
Anecdotal observation suggests an increase in the prevalence of various autoimmune diseases in the family history of
children diagnosed with AGS. However, despite the evidence
of AGS related mutations in some individuals from SLE
populations, this has never been explored in families of AGS
aﬀected persons. The purpose of this study was to investigate
this anecdotal observation to determine if there is an increase
in prevalence of autoimmune disease in families who have
children with a diagnosis of AGS, as compared to control
families.

2. Materials and Methods
To investigate the possible increase in prevalence of autoimmune disease in family members of children with AGS,
pedigrees were analyzed from families with AGS and controls
who either had a definitive diagnosis other than AGS or who
had unsolved (i.e., undiagnosed) leukodystrophies without
any features of AGS (including clinical and neuroradiological
findings). AGS cases were defined by having consistent
clinical features (elevated alpha interferon and white blood
cells in CSF, central nervous system calcifications, and
leukoencephalopathy and no other identifiable etiology) and
by confirmed mutations in any of the known AGS related
genes.
Autoimmune disease is a broad term and, for the purposes of this study, was considered to include autoimmune
thyroiditis leading to hypothyroidism, and other autoimmune thyroid dysfunction, inflammatory bowel disease, type
I diabetes, rheumatoid arthritis, multiple sclerosis, Raynaud
syndrome, psoriasis, scleroderma, Addison disease, and
Kawasaki disease, [18–20] as well as the above mentioned
autoimmune diseases (i.e., systemic lupus erythematosus
and familial chilblain lupus) already known to be associated
with AGS related genes.
The presence of autoimmune disease was investigated
in case and control families using semistructured interviews
to inquire about autoimmune disease generally and about
the presence of specific autoimmune diseases (lupus, thyroid
dysfunction, inflammatory bowel disease, type I diabetes,
rheumatoid arthritis, multiple sclerosis, and autoimmune
skin disorders). Data was collected between September 2008
and October 2011. Pedigrees for AGS subjects were drawn
during AGS family clinic/conferences in 2008 and 2011
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at Children’s National Medical Center, or during clinical
encounters in Washington DC or in Pavia, Italy. Pedigrees
for control subjects were drawn during clinical encounters
in Washington, DC by the same staﬀ as performed AGS
pedigrees. Pedigrees were excluded if there was insuﬃcient
information from one side of the family or if the patient
was adopted and family history information was limited.
Consanguineous families were included in both cases and
controls. Pedigrees were drawn by genetic counselors or a
pediatric neurologist with special expertise in biochemical
genetics and leukodystrophy.
Data collection was part of a larger data collection eﬀort
within the European NIMBL (Nuclease Immune Mediated
Brain and Lupus-like conditions) project. Italian families
who participated to this study were enrolled in NIMBL
in collaboration with the International Aicardi Goutieres
Syndrome Association (IAGSA). United States families were
enrolled in NIMBL in collaboration with the Myelin Disorders Bioregistry Project. The project was approved by the
Institutional Review Board at Children’s National Medical
Center and the ethical review boards at the Child Neurology
and Psychiatry Unit at the C. Mondino National Institute of
Neurology, Pavia, Italy.
The prevalence of autoimmune disease was investigated
all relatives combined, in parents only, and in second degree
relatives only. In this study, half-siblings of parents were also
considered to be second-degree relatives and were included
in the analysis. Siblings and half-siblings of patients were not
included in the analysis, as most of them were too young to
have exhibited any features of autoimmune disease and may
or may not develop autoimmune disease in the future.
Chi-square and/or logistic regression were used to assess
diﬀerences between overall relatives, between maternal relatives and paternal relatives, between mothers and fathers, and
between second-degree relatives in cases and controls.

3. Results
Pedigrees of families of children with AGS (N = 31) were
compared with control pedigrees of families of children
without AGS (N = 31). The US site collected family history
information on 17 of the AGS families, while the Italian
group collected family history on 14 families. Pedigrees were
collected in a prospective fashion.
Controls were all from the Myelin Disorders Bioregistry at Children’s National Medical Center in Washington, DC. Controls were patients who either had a clinical or molecular diagnosis other than AGS, or had an
undetermined diagnosis but without features of AGS.
Control diagnoses included Alexander disease, metachromatic leukodystrophy (MLD), hypomyelination with hypogonadotrophic hypogonadism and hypodontia (4H) syndrome, mucopolysaccharidosis IIIc, multiple sulfatase deficiency, congenital cytomegalovirus (CMV), acute disseminated encephalomyelitis (ADEM), and peroxisomal disorders.
Comparisons of autoimmune disease diagnoses were
assessed in relatives of AGS patients and control patients
using chi-square and logistic regression (Tables 1 and 2).
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Table 1: History of autoimmune disease in parents of cases and controls.
Characteristic
Maternal history of AI (yes/no)
No
Yes
Paternal history of AI (yes/no)
No
Yes
Maternal and/or paternal history of AI (yes/no)
No
Yes
∗P

AGS cases

Control

OR

P value

95% CI

26 (83.9%)
5 (16.1%)

28 (90.3%)
3 (9.7%)

1.00
1.75

0.453

0.39–8.27

30 (96.8%)
1 (3.2%)

31 (100.0%)
0 (0.0%)

1.00
—

0.313∗

—

25 (80.7%)
6 (19.4%)

28 (90.3%)
3 (9.7%)

1.00
2.24

0.288

0.51–9.91

value from chi-squared test due to zero control subjects with a paternal history of AI.

Table 2: History of autoimmune disease in second degree relatives of cases and controls.
Characteristic
AGS cases
Control
OR P value 95% CI
All second degree relatives both matrilineal and patrilineal with history of AI (yes/no)
No
11 (35.5%) 19 (61.3%) 1.00
Yes
20 (64.5%) 12 (38.7%) 2.88 0.044 1.03–8.07

First, a chi-square test was performed to assess diﬀerences
in reports of autoimmune diseases in the two groups. The
number of relatives with reported autoimmune disease is significantly related to having a family member with AGS (χ 2 =
6.25, P = 0.01): there were 320 total relatives of patients
with AGS, and 35 (10.9%) had reported autoimmune disease
diagnoses, compared to 5.2% (18/344) controls. Thus, the
prevalence of autoimmune disease in AGS families was more
than twice that of the control families.
Next, a chi-square calculation was performed on maternal versus paternal relatives. There was a greater percent
of maternal relatives with reported autoimmune disease
(24/164, or 14.6%) compared to controls (12/176, or 6.8%),
and this association was statistically significant (P = 0.03).
For paternal relatives, the association between having diagnosis of an autoimmune disease and having a relative with
AGS was not significant.
Using logistic regression, when looking at all first degree
relatives (mothers and fathers of cases and controls) alone,
patients with AGS were not significantly more likely to have
a parent with a reported autoimmune disease (OR = 2.24;
P = 0.29; 95% CI = 0.51–9.91). Of note, however, all of the
parents who were reported to have autoimmune disease
were in the US-based cohort of families (Table 1). If the
US cohort is considered alone (Table 3), patients with AGS
were statistically significantly more likely to have a parent
with reported autoimmune disease (OR = 5.09; P = 0.040;
95% CI= 1.07–24.02). Reports of autoimmune diseases in
first degree relatives of children with AGS included diagnoses
of: thyroid dysfunction, psoriasis, lupus-like symptoms, and
ulcerative colitis.
Logistic regression was again used for second-degree
relatives alone (grandparents, aunts, and uncles of patients
(Table 2)). Patients with AGS were significantly more likely
to have at least one second degree relative with autoimmune
disease compared to controls (OR = 2.88, P = 0.044,

95% CI = 1.03–8.07) (Table 2). A linear trend test was
performed to determine if the odds ratio increased with
increasing numbers of second degree relatives with reported
autoimmune disease. There was evidence suggestive of a
trend in the number of maternal family members (P =
0.086), but not in the number of paternal family members.
Reports of autoimmune disease diagnoses in this group
of second-degree relatives of AGS included: chilblains,
sarcoidosis, psoriasis, lupus, inflammatory bowel disease,
Raynaud’s, scleroderma, multiple sclerosis, thyroid dysfunction, and rheumatoid arthritis. Individual numbers were
too small to make meaningful comments about subsets
of autoimmune disorders, specifically SLE, seen in this
population.
Because there was a diﬀerence in the report of autoimmune disease diagnoses between females (mothers) versus
males (fathers), an assessment of diﬀerences in female versus
male second-degree relatives’ report of autoimmune disease
diagnoses was performed. Among the 29 second-degree
relatives in the AGS group who were reported to have
autoimmune disease diagnoses, 21 (72.4%) were female and
8 (27.6%) were male. Among the 15 individuals in the
control group who were reported to have an autoimmune
disease diagnosis, 10 (66.7%) were female and 5 (33.3%)
were male.

4. Discussion
Anecdotal evidence of an increased prevalence of autoimmune disease in family members of patients with AGS
prompted this analysis of pedigrees of AGS patients in comparison to control families. AGS is part of a growing group
of inherited disorders in which increased alpha interferon
is thought to play a substantial role in the pathogenesis
[21]. Familial increases in alpha interferon has been shown
to aggregate with increased risk of established autoimmune
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Table 3: Comparison of autoimmune disease reported in first degree relatives in US-based cohort only.

Characteristic
Maternal and/or paternal history of AI (yes/no)
No
Yes

AGS cases

Control

OR

P value

95% CI

11 (64.7%)
6 (35.3%)

28 (90.3%)
3 (9.7%)

1.00
5.09

0.040

1.07–24.02

disorders such as SLE [22] and juvenile dermatomyositis
[23]. Thus, it is not surprising that there is a greater
percentage of relatives of patients with AGS with reported
autoimmune disease compared to controls, and that this
association was statistically significant. It should be noted
that this statistically significant association held for maternal
relatives, but not so for paternal relatives. Patients with
AGS in the US cohort alone were shown to be statistically
significantly more likely to have a parent with autoimmune
disease compared to controls.
To explain the diﬀerence between the US and Italian
cohorts, genotype was considered, since a larger proportion
of in the Italian group of AGS patients had mutations
in RNASEH2B, but removing those from the analysis did
not result in any substantial change in findings. Thus,
this diﬀerence is not understood and requires additional
investigation. It is likely that the sample size is simply too
small to detect meaningful diﬀerences.
Statistical analysis did show that children with AGS were
significantly more likely to have at least one second degree
relative with autoimmune disease as compared to controls.
The finding of an increase in prevalence in females as
compared to males was unexpected, although it is consistent
with data showing that, in general, women are 2-3 times
more likely to have autoimmune disease than men [18].
Although diﬃcult to capture due to the variability of autoimmune diseases, the prevalence of autoimmune disease in
the US may be approximately 1/31 or 3.2% [18]. Our control
population was found to have a slightly higher prevalence
of autoimmune diseases, but our case population was found
to have significantly more than this rate. The slight increase
in prevalence in controls may be due to the fact that our
controls were drawn from children with other neurogenetic
diseases. Assessing diﬀerences in prevalence of autoimmune
diseases in pedigrees of AGS families and pedigrees of
families without any neurogenetic disease may provide a
more accurate comparison.
It is unclear at this time whether the increased prevalence
of autoimmune disease in relatives of AGS patients is
directly related to mutation status in these relatives. Of note,
although parents were generally presumed to be carriers of
mutations in AGS-related genes, the genotype of second
degree relatives with reported autoimmune disorders was not
known. In addition, it is unknown whether other genetic
modifiers exist that could change the phenotypic expression
of mutations in AGS related genes, which may predispose
related individuals to autoimmune diseases. Finally, other
factors may exist, including the fact that families with a
diagnosis of AGS may be more attentive to symptoms of
autoimmune disorders than control families, or that other
familial confounders may exist, such as diet, environment

or infection. This may explain diﬀerences seen between the
US and Italian cohorts, for example. Therefore, there is not
enough evidence or understanding at this time to claim that
individuals with diagnosed autoimmune diseases should be
screened for mutations in AGS-related genes, or that family
members of AGS patients known to carry a heterozygous
mutation should be screened for autoimmune disorders.
However, it is of note that TREX 1 mutations have been
found in patients with SLE. The relative risk for the development of SLE among those who carry TREX1 variants has
been found to be 25.3 (95% CI = 5.6–232.0) in one cohort
(N = 317) [9]. In another recently studied large cohort of
SLE patient (N = 8730), mutations in TREX1 one occurred
at a frequency of 0.5% [10]. This data, in addition to our
finding of increased prevalence of autoimmune disease in
family members of AGS patients, suggests the need for
further research into genotype-phenotype correlations of
AGS related mutations and autoimmune disease.

5. Limitations
Because family history data was obtained by report of parents
of cases and controls, and not by primary analysis of family
members’ medical records, data may be inaccurate in both
cases and controls. It is possible that both families of patients
with AGS and control patients experienced recall bias or that
they were not aware of autoimmune diagnoses in the family,
and, thus, prevalence of autoimmune disease in both groups
may be underreported. Additionally, because the semistructured interviews for family history information were
done at diﬀerent times and by diﬀerent investigators, not all
cases and controls were asked about the same conditions in
the same way, although every attempt was made to make the
data as consistent as possible, including the use of the same
group of investigators to collect control and AGS pedigrees.
One consanguineous case family and one consanguineous control family were included in the analysis. This was
unlikely to have had an eﬀect on the data, since second degree
relatives of aﬀected children were likely still only at 50% risk
of having inherited a heterozygous mutation from a parent.
There were no reports of aﬀected individuals in either the
case or control family in previous generations.
AGS is a rare disorder, and therefore, sample sizes are
small. However, the disease may be underdiagnosed. As
awareness of AGS grows and additional patients are diagnosed, more family history data will be available. Also, as
the understanding of the autoimmune nature of this disease
improves, more robust conclusions can be drawn about the
association and risk for developing autoimmune disease in
obligate or presumed carriers.
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6. Conclusion
In this evaluation of family pedigrees from patients with
Aicardi-Goutières Syndrome and control subjects, relatives
of patients with AGS reported autoimmune disease diagnoses more frequently than family members of control
patients; patients with AGS in the US-based cohort alone
were statistically more likely to have a first-degree relative
with an autoimmune disease and the entire cohort was found
to be statistically more likely compared to controls to have at
least one second-degree relative with autoimmune disease.
Female relatives reported autoimmune disease diagnoses
more frequently than male relatives. This data, in addition
to the presumed autoimmune nature of AGS and the fact
that genes that cause AGS (i.e., TREX1 and SAMHD1) are
allelic to those that can cause SLE and FCL, warrants further
study into the association between heterozygous mutations
in AGS-related genes and autoimmune disease. There is not
enough data to suggest that heterozygous carriers of mutations in AGS-related genes are at risk for developing autoimmune disease, nor that those individuals with autoimmune
disease should be screened for mutations in these genes, but
further work is needed to better understand the association.

Acknowledgments
We would like to thank the families for their cooperation in
the work presented here. The research leading to these results
has received funding from the European Union’s Seventh
Framework Program (FP7/2007–2013) under Grant no.
241779. The authors’ would like to thank Dr. Yanick Crow for
his guidance and leadership in eﬀorts towards learning about
AGS. They would also like to thank Dr. Miriam Bloom, Dr.
Philip Pearl, Dr. Sally Evans, and Dr. Umberto Balottin for
their help in evaluation of the patients and families studied.

References
[1] Y. J. Crow and J. H. Livingston, “Aicardi-Goutières syndrome:
an important Mendelian mimic of congenital infection,”
Developmental Medicine and Child Neurology, vol. 50, no. 6,
pp. 410–416, 2008.
[2] P. Lebon, J. Badoual, G. Ponsot, F. Goutieres, F. HemeuryCukier, and J. Aicardi, “Intrathecal synthesis of interferon-α
in infants with progressive familial encephalopathy,” Journal of
the Neurological Sciences, vol. 84, no. 2-3, pp. 201–208, 1988.
[3] N. Blau, L. Bonafé, I. Krägeloh-Mann et al., “Cerebrospinal
fluid pterins and folates in Aicardi-Goutières syndrome: a new
phenotype,” Neurology, vol. 61, no. 5, pp. 642–647, 2003.
[4] E. Wassmer, J. Singh, S. Agrawal, S. Santra, and Y. J. Crow,
“Elevated pterins in cerebral spinal fluid—biochemical marker
of Aicardi-Goutières syndrome,” Developmental Medicine and
Child Neurology, vol. 51, no. 10, pp. 841–842, 2009.
[5] J. Aicardi and F. Goutieres, “Systemic lupus erythematosus or
Aicardi-Goutières syndrome?” Neuropediatrics, vol. 31, no. 3,
article 113, 2000.
[6] Y. J. Crow, D. N. Black, M. Ali et al., “Cree encephalitis is
allelic with aicardi-goutières syndrome: implications for the
pathogenesis of disorders of interferon α metabolism,” Journal
of Medical Genetics, vol. 40, no. 3, pp. 183–187, 2003.

5
[7] C. de Laet, P. Goyens, C. Christophe, A. Ferster, F. Mascart, and
B. Dan, “Phenotypic overlap between infantile systemic lupus
erythematosus and Aicardi-Goutières syndrome,” Neuropediatrics, vol. 36, no. 6, pp. 399–402, 2005.
[8] R. C. Dale, S. Ping Tang, J. Z. Heckmatt, and F. M. Tatnall, “Familial systemic lupus erythematosus and congenital
infection-like syndrome,” Neuropediatrics, vol. 31, no. 3, pp.
155–158, 2000.
[9] M. A. Lee-Kirsch, M. Gong, D. Chowdhury et al., “Mutations
in the gene encoding the 3 -5 DNA exonuclease TREX1 are
associated with systemic lupus erythematosus,” Nature Genetics, vol. 39, no. 9, pp. 1065–1067, 2007.
[10] B. Namjou, P. H. Kothari, J. A. Kelly et al., “Evaluation of the
TREX1 gene in a large multi-ancestral lupus cohort,” Genes
and Immunity, vol. 12, no. 4, pp. 270–279, 2011.
[11] C. Günther, M. Meurer, A. Stein, A. Viehweg, and M. A.
Lee-Kirsch, “Familial chilblain lupus—a monogenic form of
cutaneous lupus erythematosus due to a heterozygous mutation in TREX1,” Dermatology, vol. 219, no. 2, pp. 162–166,
2009.
[12] G. Rice, W. G. Newman, J. Dean et al., “Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant
Aicardi-Goutières syndrome,” American Journal of Human
Genetics, vol. 80, no. 4, pp. 811–815, 2007.
[13] J. C. Ravenscroft, M. Suri, G. I. Rice, M. Szynkiewicz, and Y.
J. Crow, “Autosomal dominant inheritance of a heterozygous
mutation in SAMHD1 causing familial chilblain lupus,”
American Journal of Medical Genetics A, vol. 155, no. 1, pp.
235–237, 2011.
[14] A. Richards, A. M. J. M. van den Maagdenberg, J. C. Jen et al.,
“C-terminal truncations in human 3 -5 DNA exonuclease
TREX1 cause autosomal dominant retinal vasculopathy with
cerebral leukodystrophy,” Nature Genetics, vol. 39, no. 9, pp.
1068–1070, 2007.
[15] D. C. Goldstone, V. Ennis-Adeniran, J. J. Hedden et al., “HIV-1
restriction factor SAMHD1 is a deoxynucleoside triphosphate
triphosphohydrolase,” Nature, vol. 480, no. 7377, pp. 379–382,
2011.
[16] G. I. Rice, J. Bond, A. Asipu et al., “Mutations involved in
Aicardi-Goutières syndrome implicate SAMHD1 as regulator
of the innate immune response,” Nature Genetics, vol. 41, no.
7, pp. 829–832, 2009.
[17] D. B. Stetson, J. S. Ko, T. Heidmann, and R. Medzhitov, “Trex1
prevents cell-intrinsic initiation of autoimmunity,” Cell, vol.
134, no. 4, pp. 587–598, 2008.
[18] D. L. Jacobson, S. J. Gangea, N. R. Roseb, and N. M.H. Graham, “Epidemiology and estimated population burden of selected autoimmune diseases in the United States,” Clinical
Immunology and Immunopathology, vol. 84, no. 3, pp. 223–
243, 1997.
[19] J. C. Prinz, “The role of T cells in psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 17, no. 3,
pp. 257–270, 2003.
[20] J. C. Diniz, R. T. Almeida, N. E. Aikawa, A. Sallum, P. T.
Sakane, and C. A. Silva, “Kawasaki disease and juvenile systemic lupus erythematosus,” Lupus, vol. 21, no. 1, pp. 89–92,
2012.
[21] Y. J. Crow, “Type I interferonopathies: a novel set of inborn
errors of immunity,” Annals of the New York Academy of Sciences, vol. 1238, no. 1, pp. 91–98, 2011.
[22] T. B. Niewold, J. Hua, T. J. A. Lehman, J. B. Harley, and M. K.
Crow, “High serum IFN-α activity is a heritable risk factor for
systemic lupus erythematosus,” Genes and Immunity, vol. 8,
no. 6, pp. 492–502, 2007.

6
[23] T. B. Niewold, S. C. Wu, M. Smith, G. A. Morgan, and L.
M. Pachman, “Familial aggregation of autoimmune disease
in juvenile dermatomyositis,” Pediatrics, vol. 127, no. 5, pp.
e1239–e1246, 2011.

Clinical and Developmental Immunology

Journal of

Obesity

Gastroenterology
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2013

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2013

The Scientific
World Journal
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2013

Journal of

Diabetes Research
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2013

Endocrinology

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2013

BioMed Research
International

Hindawi Publishing Corporation
http://www.hindawi.com

ISRN
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com

MEDIATORS
of

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2013

ISRN
Biomarkers
Volume 2013

Volume 2013

INFLAMMATION

Computational and
Mathematical Methods
in Medicine

Oxidative Medicine and
Cellular Longevity
Volume 2013

Volume 2013

Research

Volume 2013

Clinical &
Developmental
Immunology

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2013

PPAR

Submit your manuscripts at
http://www.hindawi.com

Hindawi Publishing Corporation
http://www.hindawi.com

Hindawi Publishing Corporation
http://www.hindawi.com

Evidence-Based
Complementary and
Alternative Medicine

International Journal of

Hindawi Publishing Corporation
http://www.hindawi.com

Journal of

Oncology

Hindawi Publishing Corporation
http://www.hindawi.com

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2013

ISRN
Addiction
Volume 2013

Hindawi Publishing Corporation
http://www.hindawi.com

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2013

ISRN
Anesthesiology
Volume 2013

Hindawi Publishing Corporation
http://www.hindawi.com

Journal of

Ophthalmology
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2013

ISRN
Allergy
Volume 2013

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2013

